标题:The impact of hypertension and renin-angiotensin system blockers on outcomes of lung cancer patients: a population-based retrospective cohort study
作者:Zhu, Linhai; Li, Jian; Qu, Xiao; Pang, Zhaofei; Cui, Lixuan; Shen, Hongchang; Liu, Qi; Du, Jiajun
作者机构:[Zhu, Linhai; Du, Jiajun] Shandong Univ, Shandong Prov Hosp, Dept Thorac Surg, 324 Jingwu Rd, Jinan 250021, Peoples R China.; [Shen, Hongchang] Shan 更多
通讯作者:Du, JJ
通讯作者地址:[Du, JJ]Shandong Univ, Shandong Prov Hosp, Dept Thorac Surg, 324 Jingwu Rd, Jinan 250021, Peoples R China.
来源:INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY
出版年:2017
卷:10
期:4
页码:4818-4826
关键词:Lung cancer; hypertension; RASBs; survival
摘要:Previous studies suggest that renin-angiotensin system blockers (RASBs) have anti-proliferative effects in several types of cancer. The aim of this study was to evaluate the impact of RASBs on outcomes of lung cancer. A total of 1463 patients with histologically confirmed lung cancer were retrospectively analyzed. We compared the clinical characteristics and survival among "non-hypertension", "hypertension without RASBs" and "hypertension with RASBs" groups. For lung cancer patients, hypertension had no significant impact on overall survival (OS) and progression-free survival (PFS) of lung cancer, while RASBs use was associated with smaller tumor size, reduced lymph node metastasis, decreased stage and improved survival in lung cancer. In the subgroup analysis based on histological type, RASBs seemed to have positive impacts on NSCLC rather than SCLC. In the NSCLC group, it was angiotensin-converting enzyme inhibitors (ACEIs) rather than angiotensin receptors-1 blockers (ARBs) playing a protective role in the survival of NSCLC patients. The use of ACEIs may significantly improve the survival of NSCLC patients through suppressing tumor growth, reducing lymph node metastasis and decreasing tumor stage. The impact of RASBs on lung cancer should be investigated in more comprehensive studies with larger population.
收录类别:SCOPUS;SCIE
资源类型:期刊论文
原文链接:https://www.scopus.com/inward/record.uri?eid=2-s2.0-85018453994&partnerID=40&md5=fbeb0eff213ba8f7bd371918e951fe62
TOP